Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 15/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315838 | 0.79 | KDM4E (0.43) | TYMPL3MBTL1 | |
| SCHEMBL21067903 | 0.78 | TYMP (0.39) | TYMPL3MBTL1 | |
| SCHEMBL6570508 | 0.77 | TYMP (0.46) | TYMPL3MBTL1ALOX15ATAD2 | |
| SCHEMBL30132270 | 0.77 | TYMP (0.52) | TYMPL3MBTL1ALOX15ATAD2 | |
| SCHEMBL14709896 | 0.76 | TYMP (0.47) | TYMPL3MBTL1ATAD2 | |
| SCHEMBL9007002 | 0.74 | TYMP (0.43) | TYMPL3MBTL1ALOX15ATAD2 | |
| SCHEMBL22851522 | 0.73 | TYMP (0.59) | TYMP | |
| SCHEMBL20599962 | 0.73 | TYMP (0.59) | TYMP | |
| SCHEMBL7074796 | 0.72 | TYMP (0.42) | TYMPL3MBTL1ALOX15NPC1 | |
| SCHEMBL14478237 | 0.71 | TYMP (0.45) | TYMPL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-01 | — | — | US | disclosed |
| EP-4472627-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118922185-A | N3-substituted uracil compounds as TRPA1 inhibitors | D·E·萧尔研究有限责任公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, SLC28A1 | TYMP 276/4885L3MBTL1 2033/4885ALOX15 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.